Trending NewsTrending NewsNASDAQ:GUTS Fractyl Health (GUTS) Stock Price, News & Analysis $0.64 0.00 (-0.48%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$0.64 +0.01 (+0.78%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Fractyl Health Stock (NASDAQ:GUTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fractyl Health alerts:Sign Up Key Stats Today's Range$0.63▼$0.6650-Day Range$0.64▼$0.9152-Week Range$0.38▼$2.45Volume747,800 shsAverage Volume1.53 million shsMarket Capitalization$101.88 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingHold Company Overview Fractyl Health, Inc. is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control. The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine. This outpatient procedure is designed to interrupt disease-driving signals between the gut and the liver, pancreas and brain, with the aim of improving glycemic control and reducing liver fat. Fractyl has conducted multiple clinical trials across North America, Europe and Asia, and holds CE mark approval in the European Union for Revita DMR. Fractyl Health is also developing next-generation therapies and combination approaches to expand the reach of its duodenal resurfacing technology. The company has initiated pivotal studies to support U.S. regulatory filings and is preparing for broader commercial roll-out following anticipated approvals. Fractyl’s management team includes industry veterans in interventional gastroenterology, clinical development and medical device commercialization, positioning the company to address the growing global burden of metabolic disease.AI Generated. May Contain Errors. Read More Fractyl Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreGUTS MarketRank™: Fractyl Health scored higher than 62% of companies evaluated by MarketBeat, and ranked 149th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingFractyl Health has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialFractyl Health has a consensus price target of $5.50, representing about 759.4% upside from its current price of $0.64.Amount of Analyst CoverageFractyl Health has only been the subject of 2 research reports in the past 90 days.Read more about Fractyl Health's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fractyl Health are expected to grow in the coming year, from ($0.53) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fractyl Health is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fractyl Health is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFractyl Health has a P/B Ratio of 9.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Fractyl Health's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.52% of the float of Fractyl Health has been sold short.Short Interest Ratio / Days to CoverFractyl Health has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fractyl Health has recently decreased by 16.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFractyl Health does not currently pay a dividend.Dividend GrowthFractyl Health does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.10 News SentimentFractyl Health has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Fractyl Health this week, compared to 5 articles on an average week.Search Interest9 people have searched for GUTS on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fractyl Health insiders have not sold or bought any company stock.Percentage Held by Insiders8.36% of the stock of Fractyl Health is held by insiders.Percentage Held by InstitutionsFractyl Health has minimal institutional ownership at this time.Read more about Fractyl Health's insider trading history. Receive GUTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fractyl Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUTS Stock News HeadlinesFractyl Health Faces Nasdaq Delisting, Plans Reverse SplitSeptember 11 at 5:10 PM | tipranks.comBronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 11 at 12:00 PM | globenewswire.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.September 13 at 1:00 AM | Porter & Company (Ad)DEADLINE ALERT for AVEX, GUTS, UWMC, HDB: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsSeptember 11 at 12:00 PM | globenewswire.comRobbins LLP Urges GUTS Stockholders Who Lost Money Investing in Fractyl Health, Inc. to Contact the Firm for Information About Leading the Class ActionSeptember 10 at 8:33 PM | prnewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)September 10 at 5:45 PM | theglobeandmail.comBronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 10 at 12:00 PM | globenewswire.comFRACTYL HEALTH, INC. INVESTORS WITH LOSSES HAVE UNTIL OCTOBER 20, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces DeadlineSeptember 10 at 10:30 AM | globenewswire.comSee More Headlines GUTS Stock Analysis - Frequently Asked Questions How have GUTS shares performed this year? Fractyl Health's stock was trading at $2.20 on January 1st, 2026. Since then, GUTS shares have decreased by 70.9% and is now trading at $0.64. How were Fractyl Health's earnings last quarter? Fractyl Health, Inc. (NASDAQ:GUTS) issued its quarterly earnings results on Monday, August, 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. Read the conference call transcript. When did Fractyl Health IPO? Fractyl Health (GUTS) raised $110 million in an initial public offering (IPO) on Friday, February 2nd 2024. The company issued 7,333,333 shares at $14.00-$16.00 per share. Who are Fractyl Health's major shareholders? Fractyl Health's top institutional investors include Nantahala Capital Management LLC (7.09%), Bank of America Corp DE (3.79%), Pale Fire Capital SE (3.14%) and General Catalyst Group Management LLC (3.07%). Insiders that own company stock include Harith Rajagopalan, Jay David Caplan, William Bradley, Ajay Royan, Ian Sheffield and Weber Lara Smith. View institutional ownership trends. How do I buy shares of Fractyl Health? Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fractyl Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/10/2026Today9/13/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026EGM 20269/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GUTS's financial health is in the Green zone, according to TradeSmith. GUTS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GUTS Previous SymbolNASDAQ:GUTS CIK1572616 Webfractyl.com Phone781-902-8800FaxN/AEmployees102Year Founded2010Price Target and Rating Average Price Target for Fractyl Health$5.50 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+759.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,362.10% Return on Assets-84.89% Debt Debt-to-Equity Ratio1.41 Current Ratio3.15 Quick Ratio3.15 Sales & Book Value Annual Sales$90 thousand Price / Sales1,131.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book9.14Miscellaneous Outstanding Shares159,180,000Free Float145,873,000Market Cap$101.88 million OptionableN/A Beta2.34 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:GUTS) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fractyl Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fractyl Health With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
